Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2020 | Myeloma: impact of Del 17p on transplantation outcomes

Morie Gertz • 30 Nov 2020
ASH 2020
Multiple Myeloma Bortezomib Lenalidomide

The high-risk abnormality del(17p) has a negative prognostic impact in patients with multiple myeloma. In this video, Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, outlines the outcomes of multiple myeloma patients with Del 17p undergoing autologous stem cell transplantation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Morie Gertz

Amyloidosis Sessions: Highlights from ISA 2022
Morie Gertz et al. • 6 Sep 2022
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis 1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
The role of allogeneic transplantation in patients with multiple myeloma 1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
The importance of identifying AH amyloidosis in patients with normal free light chain levels 1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals